Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
N109208-5g | 5g | In stock | $9.90 | |
N109208-25g | 25g | In stock | $28.90 | |
N109208-100g | 100g | In stock | $79.90 | |
N109208-500g | 500g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $279.90 |
Nitric oxide synthase inhibitor
Synonyms | NCGC00024716-09 | Spectrum3_001083 | Arginine, omega-nitro-, L- | KBio1_001016 | Q7041453 | SR-01000597670 | N(sup G)-Nitro-L-arginine | N-Nitro-L-arginine | (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoic acid | EN300-204408 | hDDAH inhibito |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Nitric oxide synthase inhibitor (K i = 4.4 μM). Cardiovascular effects. Active in vivo . |
Shipped In | Normal |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of Endothelial NOS;Inhibitor of Inducible NOS;Inhibitor of Neuronal NOS |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Nω-Nitro-L-arginine displays potent inhibition of NOS with selectivity for NOS1 and NOS3 over NOS2. It has been observed to inhibit endothelial nitric oxide biosynthesis and decrease radical generation of peroxynitrite ions. Other inhibitory effects demonstrated in experiments include blocking brady-kinin-induced relaxation in dog coronary artery strips and suppressing morphine tolerance in mice. N G-Nitro-L-arginine causes significant vasoconstriction and is utilized in studying nitric oxide as a neuronal messenger. Application Nω-Nitro-L-arginine has been used:as nitric oxide synthase (NOS) inhibitor, to measure the release of nitric oxide (NO) derivatives in cytochrome c reduction assay to pretreat fiber bundles for contractile studies;as NOS inhibitor to characterize the generation of NO in Taxus yunnanensis cells;as an irreversible inhibitor of the neuronal NO synthase (nNOS) to preincubate swimbladder preparations. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 488189759 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488189759 |
IUPAC Name | (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoic acid |
INCHI | InChI=1S/C6H13N5O4/c7-4(5(12)13)2-1-3-9-6(8)10-11(14)15/h4H,1-3,7H2,(H,12,13)(H3,8,9,10)/t4-/m0/s1 |
InChi Key | MRAUNPAHJZDYCK-BYPYZUCNSA-N |
Canonical SMILES | C(CC(C(=O)O)N)CN=C(N)N[N+](=O)[O-] |
Isomeric SMILES | C(C[C@@H](C(=O)O)N)CN=C(N)N[N+](=O)[O-] |
WGK Germany | 3 |
RTECS | RM2982100 |
PubChem CID | 440005 |
Molecular Weight | 219.2 |
Beilstein | 1728914 |
Reaxy-Rn | 1728914 |
PubChem CID | 440005 |
---|---|
CAS Registry No. | 2149-70-4 |
Wikipedia | Nitroarginine |
ChEMBL Ligand | CHEMBL227744 |
RCSB PDB Ligand | NRG |
PEP | l-nna |
PubChem SID | 488189759 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B23021141 | Certificate of Analysis | Nov 08, 2022 | N109208 |
B23021142 | Certificate of Analysis | Nov 08, 2022 | N109208 |
B23021153 | Certificate of Analysis | Nov 08, 2022 | N109208 |
B23021154 | Certificate of Analysis | Nov 08, 2022 | N109208 |
B23021155 | Certificate of Analysis | Nov 08, 2022 | N109208 |
B23021156 | Certificate of Analysis | Nov 08, 2022 | N109208 |
B23021169 | Certificate of Analysis | Nov 08, 2022 | N109208 |
Solubility | Soluble in 0.1N HCl (moderately), and water (5 mM). |
---|---|
Specific Rotation[α] | [a]20/D +23.0 to +31.0 deg(C=2,2mol/L HCl) |
Melt Point(°C) | 257°C |
WGK Germany | 3 |
---|---|
RTECS | RM2982100 |
Reaxy-Rn | 1728914 |
1. Collins JL, Shearer BG, Oplinger JA, Lee S, Garvey EP, Salter M, Duffy C, Burnette TC, Furfine ES. (1998) N-Phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: structure-activity studies and demonstration of in vivo activity.. J Med Chem, 41 (15): (2858-71). [PMID:9667974] |
2. Al-Shboul OA et al.. (2019) Changes in Gastric Smooth Muscle Cell Contraction during Pregnancy: Effect of Estrogen.. J Pregnancy, 2019 (4302309). [PMID:31080672] |
3. Al-Shboul OA et al.. (2018) Effect of progesterone on nitric oxide/cyclic guanosine monophosphate signaling and contraction in gastric smooth muscle cells.. Biomed Rep, 9 (6): (511-516). [PMID:30546879] |
4. Al-Shboul OA et al.. (2018) Estrogen relaxes gastric muscle cells via a nitric oxide- and cyclic guanosine monophosphate-dependent mechanism: A sex-associated differential effect.. Exp Ther Med, 16 (3): (1685-1692). [PMID:30186388] |